Cognitive function and academic performance in neurofibromatosis 1: Consensus statement from the NF1 cognitive disorders task force

Neurology

Volumn 48, Issue 4, 1997, Pages 1121-1127

  North, K N ^a   Riccardi, V ^b   Samango Sprouse, C ^c   Ferner, R ^d   Moore, B ^e   Legius, E ^f   Ratner, N ^g   Denckla, M B ^h  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b The Neurofibromatosis Institute   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF CINCINNATI   (United States)

^h KENNEDY KRIEGER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CHROMOSOME 17; COGNITION; HUMAN; LEARNING DISORDER; MENTAL DEFICIENCY; NEUROFIBROMATOSIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL;

EID: 0030937491     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.48.4.1121     Document Type: Article

References (57)

1. Huson SM. Recent developments in the diagnosis and management of neurofibromatosis. Arch Dis Child 1989;64:745-749.
2. Riccardi VM. Neurofibromatosis. Phenotype, natural history and pathogenesis. 2nd ed. Baltimore: Johns Hopkins University Press, 1992:88-85.
3. North K, Joy P, Yuille D, Cocks N, Hutchins P. Cognitive function and academic performance in children with neurofibromatosis type 1. Dev Med Child Neurol 1995;37:427-436.
4. Denckla MD, Hofman K, Mazzocco MMM, et al. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet 1996;67:98-102.
5. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990;249:181-186.
6. Cawthon RM, Weiss M, Xu G, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990;62:193-201.
7. Xu G, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990;62: 599-608.
8. Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 1991;88:9658-9662.
9. DeClue JE, Cohen BD, Lowy DR. Identification and characterization of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA 1991;88:9914-9918.
10. Legius EM, Marchuk DA, Collins FS, Glover TW. Somatic deletion of neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nature Genet 1993;122-126.
11. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994;330:597-601.
12. Colman SD, Williams CA, Wallace MR. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nature Genet 1995;11:90-92.
13. Crowe FW, Schull WJ, Neel JV. A clinical, pathological and genetic study of multiple neurofibromatosis. Springfield IL: Charles C Thomas, 1956:1-181.
14. North K, Joy P, Yuille D, et al. Learning difficulties in neurofibromatosis type 1: the significance of MRI abnormalities. Neurology 1994;44:878-883.
15. Moore BD, Ater JL, Needle MN, Slopis J, Copeland DR. Neuropsychological profile of children with neurofibromatosis, brain tumor or both. J Child Neurol 1994;9:368-377.
16. Riccardi VM, Eichner JE. Neurofibromatosis. Phenotype, natural history and pathogenesis. Baltimore: Johns Hopkins University Press, 1986.
17. Ferner RE, Hughes RAC, Wenman J. Intellectual impairment in neurofibromatosis 1. J Neurol Sci 1996;138:125-133.
18. Huson SM, Harper PS, Compston DAS. Von Recklinghausen neurofibromatosis: a clinical and population study in south east Wales. Brain 1988;111:1355-81.
19. National Joint Committee on Learning Disabilities (NJCLD). Learning disabilities: issues on definition. ASHA 1982;24:945.
20. Eliason MJ. Neurofibromatosis: implications for learning and behaviour. J Dev Behav Pediatr 1986;7:175-179.
21. Varnhagen CK, Lewin S, Das JP, Bowen P, Ma K, Klimek M. Neurofibromatosis and psychological processes. J Dev Behav Pediatr 1988;9:257-265.
22. Stine SB, Adams WV. Learning problems in neurofibromatosis patients. Clin Orthop 1989;245:43-48.
23. Eldridge R, Denckla MB, Bien E, et al. Neurofibromatosis type 1 (Recklinghausen's disease): neurologic and cognitive assessment with sibling controls. Am J Dis Child 1989;143: 833-837.
24. Legius EM, Descheemaeker MJ, Spaepen A, Casaer P, Fryns JP. Neurofibromatosis type 1 in childhood: a study of the neuropsychological profile in 45 children. Genet Couns 1994;5: 51-60.
25. Hofman KJ, Harris EL, Bryan RN, Denckla MB. Neurofibromatosis type 1: the cognitive phenotype. J Pediatr 1994;124: S1-8.
26. Riccardi VM. Type 1 neurofibromatosis and the pediatric patient. Curr Probl Pediatr 1992;22:66-107.
27. Wadsby M, Lindenhammer H, Eeg-Olofsson O. Neurofibromatosis in childhood: neuropsychological aspects. Neurofibromatosis 1989;2:251-260.
28. Benton A, Varney N, Hamsher K. Judgement of line orientation. Iowa: Department of Neurology, University of Iowa, 1976.
29. Mazzocco MMM, Turner JE, Denckla MB, Hofman KJ, Scanlon DC, Vellutino FR. Language and reading deficits associated with neurofibromatosis type 1: evidence for not-so-nonverbal learning disability. Dev Neuropsych 1995;11:503-522.
30. Joy P, Roberts C, North K, De Silva M. Neuropsychological function and MRI abnormalities in Neurofibromatosis type 1. Dev Med Child Neurol 1995;37:906-914.
31. Bollag G, McCormick F. Differential regulation of Ras GAP and neurofibromatosis gene product activities. Nature 1991; 351:576-579.
32. Daston MM, Scrable H, Norlund M, Sturbaum AK, Nissen LM, Ratner N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells and oligodendrocytes. Neuron 1992;8:415-428.
33. Daston MM, Ratner N. Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development. Dev Dynam 1993;195:216-226.
34. Huynh DP, Nechiporuk T, Pulst SM. Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development. Dev Biol 1994;161:538-551.
35. Gutmann DH, Geist RT, Wright DE, Snier WD. Expression of the neurofibromatosis type 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Dev 1995;6:315-322.
36. Bognanno JR, Edwards MK, Lee TA, Dunn DW, Roos KL, Klatte EC. Cranial MR imaging in neurofibromatosis. Am J Neuroradiol 1988;9:461-468.
37. Dunn DW, Roos KL. MRI evaluation of learning difficulties and incoordination in neurofibromatosis type 1. Neurofibromatosis 1989;2:1-5.
38. Aoki S, Barkovich AJ, Nishimura K, et al. Neurofibromatosis types 1 and 2: cranial MR findings. Radiology 1989;172:527-534.
39. Duffner PK, Cohen ME, Seidel FG, Shucard DW. The significance of MRI abnormalities in children with neurofibromatosis. Neurology 1989;39:373-378.
40. Sevick RJ, Barkovich AJ, Edwards MSB, Koch T, Berg B, Lempert T. Evolution of white matter lesions in neurofibromatosis type 1: MR findings. Am J Radiol 1992;159:171-175.
41. DiMario FJ, Ramsby G, Greenstein R, Langshur S, Dunham B. Neurofibromatosis type 1: magnetic resonance imaging findings. J Child Neurol 1993;8:32-39.
42. Itoh T, Magnaldi S, White RM, et al. Neurofibromatosis type 1: the evolution of deep gray and white matter MR abnormalities. Am J Neuroradiol 1994;15:1513-1519.
43. Ferner RE, Chauduri R, Bingham J, Cox T, Hughes RAC. MRI in neurofibromatosis 1. The nature and evolution of increased intensity T2 weighted lesions and their relationship to intellectual impairment. J Neurol Neurosurg Psychiatry 1993; 56:492-495.
44. Mott S, Kkryja PB, Baumgardner T, Abrams M, Reiss A, Denckla M. Neurofibromatosis type I (NF1): association between volumes of T2-weighted high intensity signals (UBOs) on magnetic resonance imaging (MRI) and impaired performance on the judgement of line orientation (JLO). Presented at the conjoint meeting of the CNS and ICNA, October 2-8, 1994, San Francisco, CA.
45. Legius E, Descheemaeker MJ, Steyaert J, et al. Neurofibromatosis type 1 in childhood: correlation of MRI findings with intelligence. J Neurol Neurosurg Psychiatry 1995;59:638-640.
46. Moore BD, Slopis JM, Schomer D, Jackson EF, Levy B. Neuropsychological significance of areas of high signal intensity on brain magnetic resonance imaging scans of children with Neurofibromatosis. Neurology 1996;46:1660-1668.
47. Rosman NP, Pearce J. The brain in multiple neurofibromatosis (von Recklinghausen's disease): a suggested neuropathological basis for the associated mental defect. Brain 1967;90: 829-838.
48. Rubinstein LJ. The malformative central nervous system lesions in the central and peripheral forms of neurofibromatosis: a neuropathological study of 22 cases. Ann NY Acad Sci 1986;486:14-29.
49. Nordlund M, Gu X, Shipley MT, Ratner N. Neurofibromin is enriched in the endoplasmic reticulum of CNS neurons. J Neurosci 1993;13:1588-1600.
50. Nordlund ML, Rizvi TA, Brannan CI, Ratner N. Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains. J Neuropathol Exp Neurol 1995;54:588-600.
51. DiPaolo DP, Zimmerman RA, Rorke LB, Zackai EH, Bilaniuk LT, Yachnis AT. Neurofibromatosis type 1: pathologic substrate of high-signal of high-signal intensity foci in the brain. Radiology 1995;195:721-724.
52. Kaplan AM, Lawson MA, Bonstelle CT, Wodrich DL. Positron emission tomography (PET) in children with NF1. Abstract 607, International Child Neurology Association Conference, San Francisco, 1994.
53. Balestri P, Lucignani G, Fois A, et al. Cerebral glucose metabolism in neurofibromatosis type 1 assessed with [18F]-2-fluoro-2-deoxy-D-glucose and PET. J Neurol Neurosurg Psychiatry 1994;57:1479-1483.
54. Castillo M, Green C, Kwock L, et al. Proton MR spectroscopy in patients with neurofibromatosis type 1: evolution of hamartomas and clinical correlation. Am J Neuroradiol 1995;16: 141-7.
55. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumor predisposition in mice heterozygous for targeted mutation in NF1. Nature Genet 1994;7:353-361.
56. Brannan CI, Perkins AS, Vogel KS, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental anomalies in heart and various neural-crest-derived tissues. Genes Dev 1994;8:1019-1029.
57. Silva AJ, Frankland PW, Marowitz Z, et al. A mouse model for the cognitive deficits associated with neurofibromatosis type 1. Nat Genet 1997 (in press).